



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of :  
NOESKE-JUNGBLUT et al. : Group Art Unit.: 1653  
Serial No.: 10/694,847 : Examiner: SNEDDEN, Sheridan  
Filed: October 29, 2003 : Docket No.: KOENIG-2D1  
Title: THROMBIN INHIBITING PEPTIDE

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**REPLY**


Sir:

In response to the Office Action mailed on October 4, 2004, applicants elect with traverse group I for further prosecution and elect the following peptide: Lys-Ile-Ser-Val-Ser-Tyr-Asp-Asn-Phe-Ala-Leu-Val-Asp-Tyr-Leu-Val-Phe-Glu-Arg-Thr-Lys-Ser-Asp-Thr-Asp.

The traversal is on the basis that the PTO has not established that it would pose an undue burden to examine the full scope of the application.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,

  
Csaba Henter, Reg. No. 50,908  
Anthony J. Zelano, Reg. No. 27,969  
Attorneys for Applicant(s)

MILLEN, WHITE, ZELANO  
& BRANIGAN, P.C.  
Arlington Courthouse Plaza 1, Suite 1400  
2200 Clarendon Boulevard  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410

Date: April 1, 2005